FDA-Approved MedicationUpdated October 2026
Zepbound Guide
Zepbound is the brand-name formulation of tirzepatide 2.5–15mg specifically FDA-approved for chronic weight management, launched by Eli Lilly in late 2023. It is chemically identical to Mounjaro but approved specifically for obesity treatment, making it eligible for different insurance coverage pathways and savings programs.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
At a Glance
How Zepbound Works
Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects. GLP-1 activation creates feelings of fullness and slows digestion; GIP activation may additionally enhance fat metabolism and energy expenditure. This twin-hormone approach produces more weight loss than any single-pathway agent.[2]
Dosing Schedule
Zepbound uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+15mg/week (maintenance)
Side Effects
Common: nausea (31%), diarrhea (23%), vomiting (13%), constipation (12%), abdominal pain (9%), injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), suicidal ideation monitoring recommended, thyroid tumor risk noted in animal models.[1][2]
This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].
Clinical Trial Results
In the SURMOUNT-1 trial, Zepbound (tirzepatide 15mg) produced an average weight loss of 22.5% (about 52 lbs) over 72 weeks — the highest of any anti-obesity medication ever studied. At 10mg, participants lost 21.4%; at 5mg, they lost 15.0%. 91% of participants lost at least 5% of body weight at the 15mg dose.[2][3]
Where to Get Zepbound
These telehealth providers offer access to tirzepatide or compounded equivalents with online consultations and home delivery.
8.1/ 10
Verified partnerRxSpan MD
Best for: physician-led, pharmacy-transparent compounded GLP-1 with brand-name options
★★★★☆4.1/5
Editorial score · methodology
$249/mosemaglutide
$329/motirzepatide
CompoundedSemaglutideTirzepatideGlutathioneNAD+LegitScript Verified
Get StartedRead full RxSpan MD review →7.4/ 10
Verified partnerLuvo Health
Best for: compounded and brand GLP-1s, oral tablets and peptides on one price list
★★★★☆3.7/5
Editorial score · methodology
$249/mosemaglutide
$339/motirzepatide
CompoundedSemaglutideTirzepatideGonadorelinNAD+LegitScript Verified
Get StartedRead full Luvo Health review →7.3/ 10
Verified partneraltRX
Best for: the only platform offering all four brand-name GLP-1s plus compounded
★★★★☆3.7/5
Editorial score · methodology
$149/mosemaglutide
$249/motirzepatide
CompoundedSemaglutideTirzepatideLegitScript VerifiedFDA Warning
Get StartedRead full altRX review →7.3/ 10
Verified partnerMEDGm
Best for: brand Wegovy, Zepbound or Ozempic access alongside cheaper compounded GLP-1
★★★★☆3.7/5
Editorial score · methodology
$179/mosemaglutide
$279/motirzepatide
CompoundedSemaglutideTirzepatide
Get StartedRead full MEDGm review →7.1/ 10
Verified partnerMEDVi
Best for: switching between compounded and brand-name GLP-1 through one provider
★★★★☆3.6/5
Editorial score · methodology
$249/mosemaglutide
CompoundedSemaglutideTirzepatideFDA Warning
Get StartedRead full MEDVi review →★★★★☆3.9/5
Editorial score · methodology
$149/moorforglipron
BrandTirzepatideOrforglipron
Get StartedRead full GoodRx review →Cost Comparison
Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[5]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose and promo availability.
| Provider | Starting Price | |
|---|---|---|
| Evernow | $49/mo | Visit |
| The Virtual NP | $75/mo | Visit |
| FORM | $95/mo | Visit |
| MEDGm | $99/mo | Visit |
| MEDVi | $99/mo | Visit |
| Kin Meds | $149/mo | Visit |
| Noom | $149/mo | Visit |
| AskRx | $299/mo | Visit |
| GoodRx | $299/mo | Visit |
| Hers | $299/mo | Visit |
| Knownwell | $299/mo | Visit |
| PreventiveMD | $299/mo | Visit |
| Aspire Health | $374/mo | Visit |
| RxSpan MD | $1069/mo | Visit |
| Vaylen | $1086/mo | Visit |
| altRX | $1249/mo | Visit |
| Effecty | $1300/mo | Visit |
| HeliMeds | $1396/mo | Visit |
| Aquivia Health | $1399/mo | Visit |
| Luvo Health | $1399/mo | Visit |
| BiltRx | $1499/mo | Visit |
| Livbetr | $1599/mo | Visit |
| Fridays | $1828/mo | Visit |
| NuuVim | $1892/mo | Visit |
Zepbound Head-to-Head Comparisons
Short-form verdict pages comparing Zepbound to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.
Zepbound vs Wegovy
Zepbound delivered 20.9% TBWL in SURMOUNT-1 vs Wegovy's 14.9% in STEP-1 — and SURMOUNT-5 head-to-head confirmed Zepbound −20.2% vs Wegovy −13.7% over 72 weeks.
Last verified 2026-08-15
Zepbound vs Mounjaro
Mounjaro and Zepbound are the same molecule (tirzepatide) from Eli Lilly — Mounjaro is FDA-labeled for type 2 diabetes; Zepbound for obesity and obstructive sleep apnea.
Last verified 2026-08-15
Zepbound vs Ozempic
Ozempic is labeled for type 2 diabetes; Zepbound for obesity and OSA. SURMOUNT-5 head-to-head: tirzepatide -20.2% vs semaglutide -13.7% at 72 weeks.
Last verified 2026-08-15
Zepbound vs Foundayo
Zepbound (tirzepatide) injection delivers ~22.5% TBWL vs Foundayo (orforglipron) oral pill ~11% — but Foundayo skips needles and has no food restriction.
Last verified 2026-08-15
Zepbound vs Saxenda
Saxenda (daily liraglutide 3 mg) delivered ~8% weight loss in SCALE; Zepbound (weekly tirzepatide) hit 20.9% in SURMOUNT-1. Saxenda keeps the pediatric and pregnancy-planning niches.
Last verified 2026-08-15
Zepbound vs Rybelsus
Rybelsus is daily oral semaglutide for T2D only (~3-5% weight loss, strict 30-min fast). Zepbound is weekly injectable tirzepatide for obesity and OSA (~20.9% weight loss).
Last verified 2026-08-15
See all drug-vs-drug verdicts.
Pivotal Zepbound Trial Walkthroughs
Endpoint-by-endpoint breakdowns of the trials that shaped the Zepbound label, with primary-source numbers and FAQs.
SURMOUNT-1
SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) to once-weekly tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. The 15-mg arm lost a mean 20.9% of body weight on the treatment-regimen estimand (NEJM publication) vs 3.1% with placebo; 91% achieved at least 5% loss and 57% achieved at least 20% loss. Every prespecified cardiometabolic measure — waist, systolic blood pressure, fasting insulin, triglycerides, HbA1c — improved. GI adverse events were dose-dependent and discontinuations for AEs ran 4.3-7.1% on tirzepatide vs 2.6% on placebo.
3 · N=2,539 · Last verified 2026-08-15
SURMOUNT-OSA
SURMOUNT-OSA is the pair of phase-3 trials that drove the December 2024 FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved for the condition. Eli Lilly ran two parallel master-protocol cohorts and reported them as one paper (Malhotra 2024 NEJM, PMID 38912654): SURMOUNT-OSA-1 (n=234) randomized adults not using positive airway pressure (PAP) therapy, and SURMOUNT-OSA-2 (n=235) randomized adults already established on PAP. After 52 weeks of weekly tirzepatide at maximum tolerated dose (10 or 15 mg), the apnea-hypopnea index dropped by 25.3 events/hour in cohort 1 (placebo-subtracted −20.0) and 29.3 events/hour in cohort 2 (placebo-subtracted −23.8). Body weight fell about 18-20%, hsCRP dropped roughly 35-40%, and systolic blood pressure fell 7-9 mmHg.
Phase 3 · N=469 · Last verified 2026-08-15
SURMOUNT-2
SURMOUNT-2 randomized 938 adults with obesity and type 2 diabetes to once-weekly tirzepatide 10 mg, 15 mg, or placebo for 72 weeks. The 15-mg arm lost a mean 14.7% of body weight on the treatment-regimen estimand versus 3.2% with placebo, and dropped HbA1c by 2.22 percentage points from a mean baseline of 8.02%. Nearly 87% of 15-mg participants reached at least 5% weight loss and 52% reached 15%, while 91% hit an HbA1c below 7%. The trial answered the question SURMOUNT-1 left open — does tirzepatide work for weight loss when diabetes is on board? — and underpinned Zepbound's positioning for the obesity-plus-T2D population.
3 · N=938 · Last verified 2026-08-15
SURMOUNT-3
SURMOUNT-3 asked the question every patient and payer wants answered: does tirzepatide still work after someone has already lost weight on lifestyle alone? Eli Lilly enrolled 806 adults with obesity into a 12-week intensive lifestyle intervention, kept the 579 who lost at least 5% of their weight, and randomized them 1:1 to tirzepatide (titrated to max-tolerated 10 mg or 15 mg) or placebo for 72 more weeks of treatment, both groups continuing the lifestyle program. From the randomization point, tirzepatide drove an additional 18.4% mean weight loss versus a 2.5% regain on placebo — a placebo-subtracted 20.8 percentage points. Total weight loss across the lead-in and randomized phases reached roughly 26% on tirzepatide. The trial directly parallels STEP-3 (semaglutide plus intensive behavioral therapy) and is the strongest evidence against the argument that GLP-1 medications only work for people who have not yet tried lifestyle changes.
3 · N=579 · Last verified 2026-08-15
Zepbound Patient Questions, Answered
Real patient questions about Zepbound pulled from named subreddits and answered with peer-reviewed trial data.
Top 10 Tirzepatide Questions from Reddit, Answered with Trial Data
10 questions · 11 PubMed citations
Last verified 2026-08-15
Top 10 GLP-1 Insurance Coverage Questions from Reddit, Answered
10 questions · 12 PubMed citations
Last verified 2026-08-15
Top 10 GLP-1 Injection Technique Questions from Reddit, Answered with FDA Labels
10 questions · 11 PubMed citations
Last verified 2026-08-15
Top 10 GLP-1 Plateau Questions from Reddit, Answered
10 questions · 10 PubMed citations
Last verified 2026-08-15
Zepbound Reference Cards
Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.
Zepbound Titration Schedule Cheat Sheet (FDA Dose Ladder, Missed-Dose Rules)
Scannable reference card for the Zepbound (tirzepatide) dose ladder pulled directly from the DailyMed Zepbound prescribing information. Six dose steps, 4 weeks per step, three maintenance tiers (5, 10, or 15 mg), a 96-hour missed-dose window, and the red-flag side effects that warrant pausing escalation. For decisions about whether to advance, the FDA label lets prescribers hold a patient at any tolerated maintenance dose — the 15 mg ceiling is the maximum, not a required target.
4 min read · Last verified 2026-08-15
GLP-1 Injection Site Rotation: 8-Week Cheat Sheet (2026)
Wegovy, Ozempic, Zepbound, and Mounjaro all share the same three FDA-approved injection sites: abdomen, front of thigh, and back of upper arm. Reusing the same spot week after week causes lipohypertrophy — thickened fatty tissue that absorbs the drug erratically, leaving appetite suppression and weight-loss results inconsistent. This cheat sheet maps the approved sites, gives an 8-week rotation example, and lists the technique mistakes that send users back to the prescriber.
4 min read · Last verified 2026-08-15
GLP-1 to GLP-1 Switching (2026 Cheat Sheet)
Wegovy → Zepbound, Ozempic → Mounjaro, Saxenda → Wegovy — FDA labels do not address head-to-head switching directly. Starting-dose matrix, wait times between drugs, and red flags during the transition on one scannable page.
5 min read · Last verified 2026-08-15
Ranked PubMed Studies on Zepbound
Curated lists of the highest-impact peer-reviewed studies on Zepbound and related GLP-1 drugs. Every PMID live-verified via PubMed esummary.
Top 10 PubMed Studies on Tirzepatide for Weight Loss (2026)
Ten peer-reviewed tirzepatide weight-loss studies anchored to the SURMOUNT program (SURMOUNT-1 through SURMOUNT-5, plus SURMOUNT-CN and SURMOUNT-OSA), the SYNERGY-NASH liver-fibrosis trial, the SUMMIT HFpEF trial, and the SURPASS-2 head-to-head against semaglutide. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-08-15
Top PubMed Studies on GLP-1 Drugs for Obstructive Sleep Apnea (2026)
Nine peer-reviewed studies that built the case for GLP-1 receptor agonists in obstructive sleep apnea (OSA). SURMOUNT-OSA (Malhotra 2024 NEJM) and its 2026 cardiometabolic-risk secondary analysis (Nature Medicine) drove the December 2024 FDA approval of Zepbound for OSA — the first medication of any class with an OSA indication. The list also covers the SCALE Sleep Apnea liraglutide trial, the Sleep AHEAD intensive-lifestyle trial and its 10-year follow-up, a CPAP-vs-liraglutide proof-of-concept RCT, the Wang/Schwab tongue-fat mechanism paper, STEP-HFpEF as adjacent context for OSA-overlap populations, and two 2025-2026 systematic reviews. Each entry includes PMID, NCT, primary endpoint, and editorial summary.
9 ranked papers · Last verified 2026-08-15
Top PubMed Studies on GLP-1 Drugs and Muscle / Lean Mass Loss (2026)
Ten peer-reviewed studies that frame the muscle-loss question on GLP-1 therapy. Most randomized data comes from DEXA substudies of obesity trials — SURMOUNT-1 (Look 2025 Diabetes Obes Metab), the retatrutide phase-2 T2D body-composition substudy (Coskun 2025 Lancet D&E), and the Hendershot 2025 JAMA Psychiatry semaglutide AUD trial — which together show roughly 25-40% of weight lost on a GLP-1 is lean mass, comparable to or slightly worse than diet/exercise weight loss. The list also covers the Lundgren 2021 NEJM liraglutide-plus-exercise RCT, the Locatelli 2024 Diabetes Care resistance-exercise review, the Karakasis 2025 network meta-analysis, the Neeland 2024 mitigation-strategies review, the Tinsley 2024 fundamental body-composition framework, the Linge 2024 Circulation muscle-mass adaptive-vs-maladaptive paper, and the Nunn 2024 activin-receptor antibody preclinical paper as adjacent muscle-preservation context. Each entry includes PMID, journal, primary endpoint where applicable, and editorial summary.
10 ranked papers · Last verified 2026-08-15
Top PubMed Studies on GLP-1 Drugs and Bone Health / Fracture Risk (2026)
Ten peer-reviewed studies that frame the emerging GLP-1 bone-health question. The evidence base is younger and thinner than for cardiovascular or kidney outcomes — most randomized data is from DEXA substudies of obesity weight-loss trials, not dedicated fracture endpoints. Rapid weight loss is known to reduce bone mineral density by roughly 1-3% at the hip and lumbar spine over 12-18 months regardless of how it is achieved, and DEXA substudies of liraglutide and semaglutide have generally found GLP-1-mediated weight loss produces comparable BMD reductions to diet-induced loss. Whether the GLP-1 receptor itself confers an independent bone-protective effect — as proposed by Iepsen's foundational 2015 JCEM trial — remains contested. RCT-level meta-analyses (Mabilleau 2014, Cheng 2019, Zhang 2025) have shown no overall fracture-risk signal in type 2 diabetes populations. Observational and pharmacovigilance work (Ko 2023 JAMA Netw Open, Xiao 2025 FAERS) point toward neutral or favorable fracture profiles versus comparators. Each entry includes PMID, journal, study type, and editorial summary.
10 ranked papers · Last verified 2026-08-15
Related Research on Zepbound
Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.
Gestational Diabetes and BMI: Causes, Weight Before Pregnancy and GLP-1 Timing
What causes gestational diabetes, how pre-pregnancy BMI and weight change between pregnancies affect risk, why treatment matters, the later type 2 diabetes risk and how to lower it, and what is known about stopping GLP-1 drugs before pregnancy.
12 min read14 citations
Hiatal Hernia and Reflux on a GLP-1: What the Evidence Shows
A hiatal hernia weakens the barrier that keeps acid down, and excess weight makes it worse. GLP-1 drugs help by cutting weight and hurt by slowing the stomach. What the evidence says about which effect wins, and for whom it does not.
8 min read5 citations
Should You Wear a CGM on a GLP-1? What the Evidence Shows
Continuous glucose monitors are marketed alongside GLP-1 drugs, but the evidence splits sharply by whether you have diabetes. What the sensor can genuinely tell you, what it cannot, and the one situation where it is a clinical necessity.
8 min read5 citations
TrumpRx GLP-1 Prices: Zepbound, Wegovy, Ozempic, Mounjaro and Foundayo
TrumpRx.gov lists Zepbound at $299 to $449, Wegovy pens at $199 then $349, the Wegovy pill at $149 to $299, Ozempic at $199 to $499, Mounjaro at $499 and Foundayo at $149 to $299 — every one identical to the manufacturer's own LillyDirect or NovoCare self-pay price.
11 min read20 citations
Pen Needles for GLP-1 Pens: Which Pen Needs One, What Size, What It Costs
Ozempic and the Wegovy FlexTouch ship with 32G 4 mm pen needles; the Mounjaro and Zepbound KwikPen do not. Which pen needs which needle, gauge and length explained, how to attach and dispose of one, and what a box costs.
11 min read13 citations
Best Time to Take Zepbound or Mounjaro: Morning or Night?
Zepbound and Mounjaro (tirzepatide) can be taken any time of day, with or without food, on the same day each week. The morning vs evening trade-offs, the 4-day missed-dose rule, the 72-hour day-change rule, injection sites, and a schedule that sticks.
10 min read7 citations
Frequently Asked Questions
FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (November 2023)
Zepbound costs vary significantly by provider and form. Brand-name versions can cost $1,000–$1,600/month without insurance. Compounded versions from telehealth providers typically range from $129–$400/month. See the cost comparison table above for current prices from top providers. Always check for manufacturer savings programs or telehealth promo codes.
Common: nausea (31%), diarrhea (23%), vomiting (13%), constipation (12%), abdominal pain (9%), injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), suicidal ideation monitoring recommended, thyroid tumor risk noted in animal models.
Zepbound requires a prescription from a licensed healthcare provider. You can get it through your primary care doctor, endocrinologist, or a telehealth platform. Telehealth providers like those listed above typically offer faster access and lower out-of-pocket costs than traditional pharmacies for compounded versions.
Sources & methodology — as of October 2026
- 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Tirzepatide · Drugs and brands
- Mounjaro · Drugs and brands
- GLP-1 receptor · Mechanism
- GIP receptor · Mechanism
- Dual agonist · Mechanism
- SURMOUNT-1 · Major trials
- SURMOUNT-OSA · Major trials
From $1069/mo
RxSpan MD